Commentary: Pattern Recognition Proteins: First Line of Defense Against Coronaviruses.
作者信息
DePietro Michael, Salzberg Marc
机构信息
Airway Therapeutics, Marietta, GA, United States.
出版信息
Front Immunol. 2022 Jan 26;13:815168. doi: 10.3389/fimmu.2022.815168. eCollection 2022.
Abstract
摘要
相似文献
1
Commentary: Pattern Recognition Proteins: First Line of Defense Against Coronaviruses.评论：模式识别蛋白：对抗冠状病毒的第一道防线。
Front Immunol. 2022 Jan 26;13:815168. doi: 10.3389/fimmu.2022.815168. eCollection 2022.
2
Coronaviruses - a new old menace.冠状病毒——新的旧威胁。
Postepy Biochem. 2021 Jan 5;66(4):303-308. doi: 10.18388/pb.2020_357. Print 2020 Dec 31.
3
The Emergence of Human Pathogenic Coronaviruses: Lectins as Antivirals for SARS-CoV-2.人致病性冠状病毒的出现：作为针对 SARS-CoV-2 的抗病毒药物的凝集素。
Curr Pharm Des. 2020;26(41):5286-5292. doi: 10.2174/1381612826666200821120409.
4
Human and novel coronavirus infections in children: a review.儿童人感染和新型冠状病毒感染：综述。
Paediatr Int Child Health. 2021 Feb;41(1):36-55. doi: 10.1080/20469047.2020.1781356. Epub 2020 Jun 25.
5
Coronaviruses and Endocrine System: A Systematic Review on Evidence and Shadows.冠状病毒与内分泌系统：证据与隐忧的系统综述
Endocr Metab Immune Disord Drug Targets. 2021;21(7):1242-1251. doi: 10.2174/1871530320666200905123332.
6
Role of the Healthcare Surface Environment in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Transmission and Potential Control Measures.医疗环境表面在严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）传播中的作用和潜在的控制措施。
Clin Infect Dis. 2021 Jun 1;72(11):2052-2061. doi: 10.1093/cid/ciaa1467.
7
Clinical characteristics of two human-to-human transmitted coronaviruses: Corona Virus Disease 2019 vs. Middle East Respiratory Syndrome Coronavirus.两种人传人冠状病毒的临床特征：2019 年冠状病毒病与中东呼吸综合征冠状病毒。
Eur Rev Med Pharmacol Sci. 2020 May;24(10):5797-5809. doi: 10.26355/eurrev_202005_21374.
8
Pathological diagnosis of Coronavirus-related nephropathy: insight from postmortem studies.冠状病毒相关性肾病的病理诊断：来自尸检研究的见解。
Crit Rev Clin Lab Sci. 2021 Dec;58(8):563-575. doi: 10.1080/10408363.2021.1944047. Epub 2021 Jul 8.
9
Epigallocatechin-3-gallate (EGCG): a potential molecule for the development of therapeutics against emerging SARS-CoV-1, MERS-CoV and SARS-CoV-2 coronaviruses.表没食子儿茶素-3-没食子酸酯（EGCG）：一种有望用于开发针对新型严重急性呼吸综合征冠状病毒1型（SARS-CoV-1）、中东呼吸综合征冠状病毒（MERS-CoV）和严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）的治疗药物的分子。
J Glob Antimicrob Resist. 2021 Sep;26:26-28. doi: 10.1016/j.jgar.2021.05.005. Epub 2021 May 27.
10
Postvaccination COVID-19 among Healthcare Workers, Israel.以色列医护人员接种疫苗后感染新冠病毒情况
Emerg Infect Dis. 2021 Jun;27(6):1761. doi: 10.3201/eid2706.210410. Epub 2021 Apr 8.
引用本文的文献
1
Unraveling the enigma: The emerging significance of pulmonary surfactant proteins in predicting, diagnosing, and managing COVID-19.揭开谜团：肺表面活性剂蛋白在预测、诊断和管理 COVID-19 中的新意义。
Immun Inflamm Dis. 2024 Jun;12(6):e1302. doi: 10.1002/iid3.1302.
2
Glutathione deficiency in the pathogenesis of SARS-CoV-2 infection and its effects upon the host immune response in severe COVID-19 disease.谷胱甘肽缺乏在严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染发病机制中的作用及其对重症2019冠状病毒病（COVID-19）宿主免疫反应的影响
Front Microbiol. 2022 Oct 6;13:979719. doi: 10.3389/fmicb.2022.979719. eCollection 2022.
3
Response: Commentary: Pattern Recognition Proteins: First Line of Defense Against Coronaviruses.回应：评论：模式识别蛋白：对抗冠状病毒的第一道防线。
Front Immunol. 2022 Apr 12;13:853015. doi: 10.3389/fimmu.2022.853015. eCollection 2022.
本文引用的文献
1
Pattern Recognition Proteins: First Line of Defense Against Coronaviruses.模式识别蛋白：对抗冠状病毒的第一道防线。
Front Immunol. 2021 Sep 23;12:652252. doi: 10.3389/fimmu.2021.652252. eCollection 2021.
2
Full-Length Recombinant hSP-D Binds and Inhibits SARS-CoV-2.全长重组人 SP-D 结合并抑制 SARS-CoV-2。
Biomolecules. 2021 Jul 28;11(8):1114. doi: 10.3390/biom11081114.
3
The role of angiopoietin-2 and surfactant protein-D levels in SARS-CoV-2-related lung injury: A prospective, observational, cohort study.血管生成素-2 和表面活性蛋白-D 水平在 SARS-CoV-2 相关肺损伤中的作用：一项前瞻性、观察性、队列研究。
J Med Virol. 2021 Oct;93(10):6008-6015. doi: 10.1002/jmv.27184. Epub 2021 Jul 16.
4
Human Surfactant Protein D Binds Spike Protein and Acts as an Entry Inhibitor of SARS-CoV-2 Pseudotyped Viral Particles.人表面活性剂蛋白 D 结合刺突蛋白并作为 SARS-CoV-2 假型病毒颗粒的进入抑制剂。
Front Immunol. 2021 May 14;12:641360. doi: 10.3389/fimmu.2021.641360. eCollection 2021.
5
Surfactant protein D and bronchopulmonary dysplasia: a new way to approach an old problem.表面活性蛋白 D 与支气管肺发育不良：一个解决老问题的新方法。
Respir Res. 2021 May 8;22(1):141. doi: 10.1186/s12931-021-01738-4.
6
A Recombinant Fragment of Human Surfactant Protein D Binds Spike Protein and Inhibits Infectivity and Replication of SARS-CoV-2 in Clinical Samples.人表面活性蛋白D的重组片段与刺突蛋白结合并抑制临床样本中SARS-CoV-2的感染性和复制。
Am J Respir Cell Mol Biol. 2021 Jul;65(1):41-53. doi: 10.1165/rcmb.2021-0005OC.
7
Are Serum Interleukin 6 and Surfactant Protein D Levels Associated with the Clinical Course of COVID-19?血清白细胞介素 6 和表面活性蛋白 D 水平与 COVID-19 的临床病程有关吗？
Lung. 2020 Oct;198(5):777-784. doi: 10.1007/s00408-020-00393-8. Epub 2020 Sep 12.
8
Supramolecular Assembly of Human Pulmonary Surfactant Protein SP-D.人肺表面活性蛋白 SP-D 的超分子组装。
J Mol Biol. 2018 May 11;430(10):1495-1509. doi: 10.1016/j.jmb.2018.03.027. Epub 2018 Apr 4.
9
Surfactant Protein D in Respiratory and Non-Respiratory Diseases.表面活性蛋白D在呼吸道疾病和非呼吸道疾病中的作用
Front Med (Lausanne). 2018 Feb 8;5:18. doi: 10.3389/fmed.2018.00018. eCollection 2018.
10
Increased prevalence of low oligomeric state surfactant protein D with restricted lectin activity in bronchoalveolar lavage fluid from preterm infants.支气管肺泡灌洗液中低寡聚状态表面活性蛋白 D 与限制性凝集素活性增加与早产儿有关。
Thorax. 2013 May;68(5):460-7. doi: 10.1136/thoraxjnl-2012-202729. Epub 2013 Feb 6.
Zotero 插件